State Of Wisconsin Investment Board Ascendis Pharma A/S Transaction History

State Of Wisconsin Investment Board

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$69.96 - $97.84 $445,015 - $622,360	6,361 Added 43.29%	21,055 $1.88 Million
Q1 2023 May 15, 2023	SELL	$104.9 - $126.78 $66,401 - $80,251	-633 Reduced 4.13%	14,694 $1.58 Million
Q4 2022 Feb 14, 2023	SELL	$99.42 - $131.97 $53,786 - $71,395	-541 Reduced 3.41%	15,327 $1.87 Million
Q3 2022 Nov 14, 2022	SELL	$84.03 - $110.23 $312,591 - $410,055	-3,720 Reduced 18.99%	15,868 $1.64 Million
Q2 2022 Aug 15, 2022	SELL	$78.08 - $117.61 $616,832 - $929,119	-7,900 Reduced 28.74%	19,588 $1.82 Million
Q1 2022 May 13, 2022	BUY	$102.18 - $135.75 $350,988 - $466,301	3,435 Added 14.28%	27,488 $3.23 Million
Q2 2021 Aug 12, 2021	BUY	$121.62 - $145.29 $414,359 - $495,003	3,407 Added 16.5%	24,053 $3.16 Million
Q1 2021 May 17, 2021	SELL	$124.92 - $173.33 $439,718 - $610,121	-3,520 Reduced 14.57%	20,646 $2.66 Million
Q4 2020 Feb 03, 2021	BUY	$151.2 - $182.76 $886,939 - $1.07 Million	5,866 Added 32.05%	24,166 $4.03 Million
Q3 2020 Nov 16, 2020	BUY	$134.29 - $154.32 $2.46 Million - $2.82 Million	18,300 New	18,300 $2.82 Million

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

Stay updated on State Of Wisconsin Investment Board with notifications on news.